PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Biomerica, Inc. (BMRA)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS09061H3075
CUSIP09061H307
SectorHealthcare
IndustryMedical Devices

Highlights

Market Cap$12.28M
EPS-$0.37
Revenue (TTM)$5.41M
Gross Profit (TTM)$446.00K
EBITDA (TTM)-$6.31M
Year Range$0.70 - $2.13
Target Price$13.00
Short %0.43%
Short Ratio1.55

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Biomerica, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Biomerica, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-20.00%0.00%20.00%40.00%60.00%80.00%NovemberDecember2024FebruaryMarchApril
-20.05%
21.13%
BMRA (Biomerica, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Biomerica, Inc. had a return of -42.96% year-to-date (YTD) and -45.57% in the last 12 months. Over the past 10 years, Biomerica, Inc. had an annualized return of -0.67%, while the S&P 500 had an annualized return of 10.55%, indicating that Biomerica, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-42.96%6.33%
1 month-18.07%-2.81%
6 months-20.08%21.13%
1 year-45.57%24.56%
5 years (annualized)-21.73%11.55%
10 years (annualized)-0.67%10.55%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-25.60%31.18%-31.80%
2023-32.80%13.93%-5.10%34.41%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BMRA is 26, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of BMRA is 2626
Biomerica, Inc.(BMRA)
The Sharpe Ratio Rank of BMRA is 2828Sharpe Ratio Rank
The Sortino Ratio Rank of BMRA is 3333Sortino Ratio Rank
The Omega Ratio Rank of BMRA is 3333Omega Ratio Rank
The Calmar Ratio Rank of BMRA is 2121Calmar Ratio Rank
The Martin Ratio Rank of BMRA is 1616Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Biomerica, Inc. (BMRA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


BMRA
Sharpe ratio
The chart of Sharpe ratio for BMRA, currently valued at -0.43, compared to the broader market-2.00-1.000.001.002.003.00-0.43
Sortino ratio
The chart of Sortino ratio for BMRA, currently valued at -0.16, compared to the broader market-4.00-2.000.002.004.006.00-0.16
Omega ratio
The chart of Omega ratio for BMRA, currently valued at 0.98, compared to the broader market0.501.001.500.98
Calmar ratio
The chart of Calmar ratio for BMRA, currently valued at -0.49, compared to the broader market0.001.002.003.004.005.006.00-0.49
Martin ratio
The chart of Martin ratio for BMRA, currently valued at -1.25, compared to the broader market0.0010.0020.0030.00-1.25
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.91, compared to the broader market-2.00-1.000.001.002.003.001.91
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.77, compared to the broader market-4.00-2.000.002.004.006.002.77
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.33, compared to the broader market0.501.001.501.33
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.46, compared to the broader market0.001.002.003.004.005.006.001.46
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.61, compared to the broader market0.0010.0020.0030.007.61

Sharpe Ratio

The current Biomerica, Inc. Sharpe ratio is -0.43. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-0.43
1.91
BMRA (Biomerica, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Biomerica, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-95.54%
-3.48%
BMRA (Biomerica, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Biomerica, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Biomerica, Inc. was 98.62%, occurring on Oct 11, 2002. Recovery took 3435 trading sessions.

The current Biomerica, Inc. drawdown is 95.54%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.62%Apr 12, 19854125Oct 11, 20023435Mar 19, 20207560
-95.56%Mar 20, 2020893Oct 5, 2023
-25%Nov 13, 198415Dec 4, 19848Dec 14, 198423
-12%Dec 27, 19844Jan 2, 19856Jan 10, 198510
-8.33%Mar 4, 19852Mar 5, 198513Mar 22, 198515

Volatility

Volatility Chart

The current Biomerica, Inc. volatility is 12.98%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%70.00%NovemberDecember2024FebruaryMarchApril
12.98%
3.59%
BMRA (Biomerica, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Biomerica, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items